Local view for "http://purl.org/linkedpolitics/eu/plenary/2010-11-24-Speech-3-193"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20101124.15.3-193"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"Advertising of prescription-only medicines is banned within the European Union, and remains so. Pharmaceutical companies must comply with clear rules on objectivity in the non-promotional information that they disseminate. These are the two important messages sent this lunchtime with the adoption of the legislative package on information for patients. A consensual vote by Parliament (558 votes to 48) that merely confirms the unanimous vote, less one vote from the Committee on the Environment, Public Health and Food Safety. Numerous safeguards have been put in place. The European Commission proposed a ban on information about prescription-only medicines broadcast on television or radio, and the European Parliament has decided to extend this to the written press. Manufacturers are subject to numerous obligations: descriptions of product characteristics, strengthened labelling, and prior authorisation by health authorities. I do not understand all the ‘commotion’ that the issue has caused, especially in French-speaking Belgium, amongst consumers’ associations and mutual societies, supported by certain MEPs who, even before the discussions had started, had already condemned these two laws. This is facile political posturing that I find regrettable, given the high expectations of patients when faced with illness and given that, without these laws, the public would be at the mercy of the cowboys on the Internet."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples